Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its third quarter 2021 financial results before markets open on Monday, November 15, 2021.

The Company will subsequently hold a conference call the same day, Monday, November 1, 2021 at 11:00 a.m. ET, hosted by Jesse Ledger, Miravo’s President & Chief Executive Officer and other senior management. A question-and-answer session will follow the corporate update.

CONFERENCE CALL DETAILS

DATE: Monday, November 15, 2021

TIME: 11:00 a.m. ET

DIAL-IN NUMBERS: (289) 536-4777 or 1 (888) 550-2239

The audio webcast and webcast replay can be accessed at:

https://onlinexperiences.com/Launch/QReg/ShowUUID=1E07F0A9-7B64-4D3F-9EAA-D9A1C0CE92B9

About Miravo Healthcare

Miravo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy, neurology and dermatology. The Company’s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Miravo’s head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company’s manufacturing facility is located in Varennes, Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S, Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the U.S. Food and Drug Administration. For additional information, please visit www.miravohealthcare.com.

Investor Relations Stefan Eftychiou 905 326 1888 ext 60 stefan@bristolir.com

Nuvo Pharmaceuticals (TSX:MRV)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Nuvo Pharmaceuticals.
Nuvo Pharmaceuticals (TSX:MRV)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Nuvo Pharmaceuticals.